University of Manchester scientists to develop Zika virus vaccine
The move is part of a new initiative to counter the disease. Researchers expect to deliver results in 18 months, working with a smallpox virus derivative that may
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
These data showed the BRIDGE study met the primary endpoint, demonstrating a statistically significant increase in bone mineral density (BMD) at the lumbar spine (as assessed by dual
"Changes at InVivo Therapeutics after I left the company in August of 2013 have permanently limited wide market adoption of my first generation of NeuroScaffolds. PixarBio’s Novel NR-SCI